Your cart is empty.
Männedorf, 2 March 2007 – Timothy B. Anderson, a long term member of Tecan’s Board of Directors, will, for personal reasons, not run for another term of office at the Annual General Meeting of the Shareholders on 19 April 2007. The Board of Directors proposes the Biopharma specialist Jürg Meier for the vacant seat on the Board.
Timothy B. Anderson, who has been a member of the Board of Directors since 2000, had indicated in internal discussions in September of last year that he might not be willing to stand for re-election, for personal reasons. The Board of Directors greatly regrets his decision and would like to take the opportunity to thank Timothy B. Anderson for his valuable work and support.
Jürg Meier, who is proposed as replacement, holds a PhD in chemistry and successfully headed the Novartis Venture Fund for more than six years. The 66 year old has more than three decades of expertise in the Research and Development in the Pharmaceutical and Biotechnology industries. Among other things, he was the Global Head of Research of the former Sandoz. “We are very happy that Mr. Meier is willing to join the Board of Directors of Tecan”, says Mike Baronian, Chairman of the Board of Directors. “His expertise in the Biopharma area will ideally complement our know-how in Diagnostic business, which is already well represented with the former Johnson&Johnson Manager Gérard Vaillant. “ Tecan achieves roughly 60 percent of its sales in Biopharma, and the rest in Diagnostics.
As announced by Tecan on 13 February 2007, Heinrich Fischer is also proposed for election as a member of the Board of Directors at the Annual General Meeting of the Shareholders on 19 April 2007. Heinrich Fischer, who will resign from his position as CEO of Saurer AG by the end of April 2007, has an excellent reputation as a manager with vast expertise in regards to the realization of external growth opportunities and has a deep understanding of the Asian markets.
Tecan (www.tecan.com) is a leading player in the life sciences supply industry. The company specializes in the development, production and distribution of automation solutions which facilitate the researching of active pharmaceutical compounds, as well as diagnostics, pharmaceutical research and forensics for clients in the life sciences sector. Through its REMP subsidiary (www.remp.com), Tecan is the leading supplier of large-scale automated storage and retrieval systems. Tecan clients are pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2005, Tecan achieved sales of CHF 344.9 million (USD 275.9 million; EUR 222.5 million). Registered shares of Tecan Group are traded on the SWX Swiss Exchange (TK: TECN/Reuters: TECZn.S/Valor: 1210019).
Tecan Group Ltd.